Inhibition of tick-borne encephalitis virus in cell cultures by ribavirin.
myxovirus resistance A
ribavirin
signal transducer and activator of transcription 3
tick-borne encephalitis virus
tumor necrosis factor alpha
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
03
2023
accepted:
24
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Tick-borne encephalitis virus (TBEV) belonging to arboviruses is a major member of zoonotic pathogens. TBEV infection causes severe human encephalitis without specific antiviral drugs. Due to its use of antiviral drug against a wide range of viruses, we investigated antiviral effect of ribavirin against TBEV in susceptible human cell lines A549 and SH-SY5Y. Ribavirin displayed minor cytotoxicity on multiple cell lines. Ribavirin obviously impaired TBEV replication and protected the infected cells from cytopathic effect. Importantly, ribavirin markedly inhibited TBEV propagation, as evidenced by impairment of TBEV production and viral RNA replication. Treatment with ribavirin (co-treatment and post-treatment) led to a dose-dependent reduction in TBEV titers as well as the viral RNA levels. Antiviral protein myxovirus resistance A mRNA expression was significantly up-regulated and signal transducer and activator of transcription 3 was activated in TBEV-infected A549 cells upon the ribavirin treatment. Induction of inflammatory cytokine tumor necrosis factor alpha by TBEV was decreased in A549 cells with the treatment of ribavirin, whereas interleukin 1 beta release appeared to be unaffected. These results suggest that ribavirin might represent a promising safe and effective antiviral drug against TBEV.
Identifiants
pubmed: 37378295
doi: 10.3389/fmicb.2023.1182798
pmc: PMC10291047
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1182798Informations de copyright
Copyright © 2023 Tang, Tang, Peng, Ren, Zhao and Zhao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Med Virol. 2022 Oct;94(10):4918-4925
pubmed: 35644833
Sci Rep. 2017 Nov 21;7(1):15931
pubmed: 29162867
Bio Protoc. 2018 May 05;8(9):e2830
pubmed: 34286039
Antivir Ther. 2013;18(4):575-84
pubmed: 23300158
Adv Ther. 2022 Sep;39(9):4037-4051
pubmed: 35876973
Antiviral Res. 2017 Jun;142:63-67
pubmed: 28336346
Viruses. 2022 Jun 24;14(7):
pubmed: 35891362
Clin Exp Immunol. 2003 Jan;131(1):148-54
pubmed: 12519399
Hepatology. 2006 Mar;43(3):581-91
pubmed: 16496340
PLoS One. 2018 Oct 9;13(10):e0205294
pubmed: 30300398
J Gen Virol. 2014 Jan;95(Pt 1):26-37
pubmed: 24114793
Pharmacol Res. 2018 Apr;130:308-315
pubmed: 29499270
J Hepatol. 2009 Feb;50(2):402-11
pubmed: 19091439
J Antimicrob Chemother. 1984 Aug;14 Suppl A:27-41
pubmed: 6208183
Ann Pharmacother. 2015 Oct;49(10):1125-35
pubmed: 26228937
Antiviral Res. 2015 Dec;124:83-92
pubmed: 26542647
Antiviral Res. 2017 Jun;142:68-75
pubmed: 28322925
J Antimicrob Chemother. 2011 Jun;66(6):1215-22
pubmed: 21482564
Curr Opin Microbiol. 2013 Aug;16(4):493-9
pubmed: 23725670
PLoS Pathog. 2018 Mar 15;14(3):e1006839
pubmed: 29543893
Vopr Virusol. 2016 Jun 28;61(3):139-144
pubmed: 36494949
Antiviral Res. 1996 May;30(2-3):125-32
pubmed: 8783804
J Immunol. 2023 Feb 1;210(3):271-282
pubmed: 36548460
Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S750-61
pubmed: 2546248
Molecules. 2019 Mar 21;24(6):
pubmed: 30901934
Front Immunol. 2018 Sep 26;9:2174
pubmed: 30319632
J Vet Med Sci. 2019 Mar 14;81(3):343-347
pubmed: 30674746
Bull Exp Biol Med. 2020 Nov;170(1):53-57
pubmed: 33222083
Bull Exp Biol Med. 2018 May;165(1):61-63
pubmed: 29797124
J Infect Dis. 2000 Oct;182(4):1214-7
pubmed: 10979920
Viruses. 2018 Jun 28;10(7):
pubmed: 29958443
Cell Microbiol. 2008 Jan;10(1):165-76
pubmed: 17697133
Emerg Infect Dis. 2022 Aug;28(8):1559-1568
pubmed: 35876478
Antimicrob Agents Chemother. 1984 Oct;26(4):476-80
pubmed: 6151377
Future Virol. 2018 Aug;13(8):557-574
pubmed: 32201498
J Interferon Cytokine Res. 2004 Nov;24(11):659-63
pubmed: 15684819
Antiviral Res. 2003 Mar;58(1):73-9
pubmed: 12719009
PLoS Negl Trop Dis. 2010 Apr 27;4(4):e624
pubmed: 20436960
Curr Opin Virol. 2014 Oct;8:10-5
pubmed: 24846716
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29035-29045
pubmed: 33144502
Interdiscip Sci. 2009 Sep;1(3):168-72
pubmed: 20640834
PLoS One. 2011;6(11):e27866
pubmed: 22114715
Cochrane Database Syst Rev. 2018 Jun 05;6:CD012713
pubmed: 29869797
Antiviral Res. 2012 Nov;96(2):260-8
pubmed: 22985631
Oncogene. 2017 May 25;36(21):3037-3047
pubmed: 27941882
J Gen Virol. 2017 Dec;98(12):3008-3025
pubmed: 29120300
J Med Virol. 2011 May;83(5):910-20
pubmed: 21360544
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(7. Vyp. 2):40-51
pubmed: 31532590
Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):
pubmed: 35177474
Virus Res. 2013 Dec 26;178(2):471-7
pubmed: 24177270
J Vector Borne Dis. 2020 Jan-Mar;57(1):14-22
pubmed: 33818450
PLoS Pathog. 2021 Jun 24;17(6):e1009636
pubmed: 34166464
Mol Cancer Ther. 2019 Jul;18(7):1185-1194
pubmed: 31263027
Arch Virol. 2017 Jun;162(6):1661-1669
pubmed: 28243801
Antiviral Res. 2016 Sep;133:119-29
pubmed: 27476046
PLoS Pathog. 2010 Jan 15;6(1):e1000721
pubmed: 20084112
J Interferon Cytokine Res. 2011 Jan;31(1):79-87
pubmed: 21166595
J Med Virol. 2023 Jan;95(1):
pubmed: 35869037
J Immunol. 1998 Apr 1;160(7):3487-93
pubmed: 9531310
Leuk Lymphoma. 2010 Oct;51(10):1805-15
pubmed: 20629523